Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine

Lancet

Volumn 358, Issue 9287, 2001, Pages 1066-1067

  Iyer, Jayasree K ^a   Milhous, Wilbur K ^b   Cortese, Joseph F ^a   Kublin, James G ^a   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COTRIMOXAZOLE; FANSIDAR; FOLIC ACID ANTAGONIST; PYRIMETHAMINE; TRIMETHOPRIM;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG SENSITIVITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MALARIA FALCIPARUM; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME;

EID: 0035968580     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06201-8     Document Type: Article

References (5)

1. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: A randomised trial
2. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: A randomised controlled trial
3. Plasmodium falciparum: Selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children
4. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs
5. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutants expressed in yeast